The activities of fluoroquinolones and a new macrolide against 30 clinical isolates of Mycobacterium tuberculosis were determined in vitro by agar diffusion. In order of relative potencies against M. tuberculosis, temafloxacin (MIC for 90% of isolates [MIC9J, 2.3 ,ug/ml) was at least as active as the reference quinolones ofloxacin (MIC90, 2.4 ,ug/ml) and ciprofloxacin (MIC90, 4.3 jig/ml). Less active were difloxacin (MIC90, 4.7 ,Ig/ml), pefloxacin (MIC90, 6.7 ,iglml), and enoxacin (MIC90, 8.3 ,ug/ml). The macrolide clarithromycin was more potent than erythromycin but less potent than the fluoroquinolones. Our results suggest that the newer fluoroquinolones and clarithromycin should be included with ciprofloxacin and ofloxacin in pharmacokinetic studies that may lead to trials in human subjects with mycobacterial infections.
The fluoroquinolones, a new class of antimicrobial agents, are structurally related to nalidixic acid and have pharmacologic and microbiologic properties attractive for their use in treating many infectious diseases caused by gram-negative and gram-positive bacteria. Good in vitro potencies against Mycobacterium tuberculosis have been reported for the fluoroquinolones ciprofloxacin (2, 3, 5, 6 ) and ofloxacin (3, 11) ; less active are norfloxacin (3, 5) and amifloxacin (3) . Clarithromycin activity has not been reported.
In this report, we compare with reference antimicrobial agents the in vitro potencies against M. tuberculosis of fluoroquinolones, difloxacin, temafloxacin, enoxacin, pefloxacin, and a new macrolide, clarithromycin.
Antimicrobial agents. The following reagent powders were synthesized and supplied by Abbott Laboratories, North Chicago, Ill.: difloxacin (activity, 850 jig/mg), temafloxacin (activity, 1,000 jig/mg), and pefloxacin (activity, 1,000 pLg/ mg); erythromycin (activity, 763 ,ug/mg) and clarithromycin (activity, 993 p.g/mg) (licensed from Taisho Pharmaceuticals)
were also prepared and supplied by Abbott Laboratories. Other reagent powders were received as gifts from their manufacturers: ciprofloxacin (activity, 858 plg/mg; Miles Pharmaceuticals, West Haven, Conn.), ofloxacin (activity, 1,000 ,ug/mg; Ortho Pharmaceuticals, Raritan, N.J.), and enoxacin (activity, 1,000 ,ug/mg; Warner Lambert, Ann Arbor, Mich.). Stock solutions (1,000 ,ug/ml) were prepared according to manufacturer instructions. Subsequent dilutions in sterile distilled water were added to molten media used in assays for the MICs of drugs.
Mycobacteria. A total of 30 clinical isolates of M. tuberculosis were recovered from sputum specimens of patients prior to treatment at the Veterans Administration Medical Center, Buffalo, N.Y. After isolation and identification, the microorganisms were stored at 4°C on Lowenstein-Jensen medium (Difco Laboratories, Detroit, Mich.). For antimicrobial susceptibility testing, an indirect method (12) was used. Briefly, the strains were subcultured in Dubos broth base enriched with Dubos medium albumin (Difco) and incubated * Corresponding author. for 7 days or until growth produced turbidity equal to a McFarland no. 1 standard.
Susceptibility testing. MICs were determined by incorporating doubling dilutions of the investigational agent (10 to 0.3 ,ug/ml) in Middlebrook 7H10 agar (Difco) prepared as slants in screw-cap test tubes (20 by 150 mm). The inoculum (0.2 ml of the standardized culture diluted 10-5) was spread over the surface of the control slant (drug free) and each antimicrobial agent slant. To eliminate expected confluent growth in control tubes and to allow for enumerating and calculating CFU per milliliter, we seeded an additional control with the inoculum diluted 1:20. The tubes were incubated at 37°C and examined for growth at 3-and 4-week intervals. The extent of growth in drug-containing tubes was compared with that in control tubes. If <1% of a population (i.e., <10 CFU of mycobacteria) failed to grow in the concentration of antimicrobial agent tested, the agent was recorded as effective at that concentration.
The MICs of arylfluoroquinolones and a new macrolide, clarithromycin, for mycobacteria are presented in Table 1 . In order of relative potencies against M. tuberculosis, temafloxacin was at least as active as the reference quinolones (ofloxacin and ciprofloxacin) and more potent than difloxacin, pefloxacin, or enoxacin; pefloxacin was the least active. Clarithromycin, the 6-0-methyl derivative of erythromycin, was more active than the latter macrolide against 12 of the 30 strains of M. tuberculosis tested. A total of 1, 3, 7, 12, and 30 strains were inhibited by clarithromycin MICs of 0.3, 2.5, 5.0, 10, and >10 xg/ml, respectively.
In vitro the growth of many Mycobacterium species, including M. tuberculosis, is suppressed by ciprofloxacin (2, 3, 5, 6) and ofloxacin (3, 11) . The current study supports these reports and extends knowledge regarding the potencies against M. tuberculosis strains of the fluoroquinolones difloxacin, temafloxacin, enoxacin, and pefloxacin. Our data showed that temafloxacin had MICs for 90% of M. tuberculosis isolates similar to those of ciprofloxacin and ofloxacin. Against all strains difloxacin, enoxacin, and pefloxacin were the least potent. Fenlon and Cynamon (3) reported MICs of ciprofloxacin and ofloxacin for 90% of M. tuberculosis isolates of 0.5 and 1 ,ug/ml, respectively, values lower than ours (4.3 and 2.4 ,ug/ml, respectively). There is an obvious advantage to testing under the same experimental conditions the potencies of a series of antimicrobial agents against the same populations of microbial isolates. Accordingly, whereas our higher values may reflect methodology, which will affect the results obtained (10), our conclusion that at least three of the reagents we tested (temafloxacin, ciprofloxacin, and ofloxacin) had similar potencies and were more active than difloxacin, enoxacin, or pefloxacin against M. tuberculosis is tenable.
The fluoroquinolones have pharmacologic and microbiologic properties acceptable for treating systemic infections (1, 9) . The use of ciprofloxacin and ofloxacin against M. tuberculosis in an animal model and in clinical trials has been proposed (3). The in vitro activity of temafloxacin in the current report and its rapid oral absorption and bioavailability in the mouse model (7) justify assessing its antimycobacterial efficacy in animal studies.
Clarithromycin was more potent than erythromycin in vitro against 12 of the 30 strains of M. tuberculosis studied; each strain was refractory to 10 ,ug of erythromycin per ml. Although the in vitro potency of clarithromycin against M. tuberculosis was marginal, study of its intracellular efficacy is justified on the basis of recent reports with animal models and other microorganisms. Fernandes and colleagues (4) reported that clarithromycin administered orally to mice was better absorbed than erythromycin and resulted in a peak level and half-life in serum higher than those of erythromycin. In addition, the latter investigators showed that clarithromycin given intraperitoneally eliminated or significantly reduced the viable population of Legionella pneumophila in the lungs and spleens of experimentally infected guinea pigs. More recently, Hastings et al. reported that administration in the feed of mice of clarithromycin, in contrast to erythromycin or roxithromycin, fully suppressed the growth of Mycobacterium leprae in the footpad (8) . In his commentary on Mycobacterium avium infection in patients with acquired immunodeficiency syndrome, Young postulated that combination approaches for delivering medications to intracellular sites of phagocytes may offer the best hope for eventual control of this systemic infection (13) .
Because mycobacterial infections have both intra-and extracellular loci, temafloxacin, difloxacin, and clarithromycin alone or in combination with compounds that have in vitro activity should be included in pharmacokinetic studies that may lead to trials in humans.
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